Sunday, February 21, 2016

Relapse Prevention Medications in Community Treatment for Young Adults with Opioid Addiction

Despite the well-known effectiveness and widespread use of relapse prevention medications such as extended release naltrexone (XR-NTX) and buprenorphine for opioid addiction in adults, less is known about their use in younger populations.

This was a naturalistic study using retrospective chart review of N = 56 serial admissions into a specialty community treatment program that featured the use of relapse prevention medications for young adults with opioid use disorders (19-26). Treatment outcomes over 24 weeks included retention, and weekly opioid negative urine tests.

Patients were mean age 23.1, 70% male, 86% Caucasian, 82% with history of injection heroin use, and treated with either buprenorphine (77%) or XR-NTX (23%). The mean number of XR-NTX doses received was 4.1. Retention was approximately 65% at 12 weeks and 40% at 24 weeks, and rates of opioid negative urine were 50% at 12 weeks and 39% at 24 weeks, with missing samples imputed as positive. There were no statistically significant differences in retention (t = 1.87, p = .06) or in rates of weekly opioid negative urine tests (t = 1.96, p = .06) between medication groups, over the course of 24 weeks. The XR-NTX group had higher rates of weekly negative urine drug tests for other non-opioid substances (t = 2.83; p < .05) compared to the buprenorphine group. Males were retained in treatment longer and had higher rates of opioid negative weeks compared to females.

Our results suggest that relapse prevention medications including both buprenorphine and XR-NTX can be effectively incorporated into standard community treatment for opioid addiction in young adults with good results. Specialty programming focused on opioid addiction in young adults may provide a promising model for further treatment development.

Purchase full article at:

By:    Vo HT1Robbins E1Westwood M1Lezama D1Fishman M1,2.
  • 1 Maryland Treatment Centers , Baltimore , MD , USA.
  • 2 Johns Hopkins School of Medicine , Baltimore , MD , USA.
  •  2016 Jan 28:0 

No comments:

Post a Comment